EntreMed Commences Clinical Trial for MKC-1 in Lung Cancer Patients
EntreMed, Inc.
(Nasdaq: ENMD), a clinical-stage pharmaceutical company developing
therapeutics for the treatment of cancer and inflammatory diseases, today
announced commencement of a multi-center study with its drug candidate,
MKC-1, in non-small cell lung cancer (NSCLC) patients.
This entry was posted on Wednesday, October 25th, 2006 at 8:27 am and is filed under Research, Treatment. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.